资源描述：
《Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.pdf》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。
1、REVIEWSTreatinginflammationbyblockinginterleukin-1inabroadspectrumofdiseasesCharlesA. Dinarello1,2,AnnaSimon2andJosW. M. vanderMeer2Abstract
2、Interleukin‑1(IL‑1)isahighlyactivepro‑inflammatorycytokinethatlowerspainthresholdsanddamagestissues.MonotherapyblockingIL‑
3、1activityinautoinflammatorysyndromesresultsinarapidandsustainedreductionindiseaseseverity,includingreversalofinflammation‑mediatedlossofsight,hearingandorganfunction.Thisapproachcanthereforebeeffectiveintreatingcommonconditionssuchaspost‑infarctionheartfailure,an
4、dtrialstargetingabroadspectrumofnewindicationsareunderway.Sofar,threeIL‑1‑targetedagentshavebeenapproved:theIL‑1receptorantagonistanakinra,thesolubledecoyreceptorrilonaceptandtheneutralizingmonoclonalanti‑IL‑1βantibodycanakinumab.Inaddition,amonoclonalantibodydir
5、ectedagainsttheIL‑1receptorandaneutralizinganti‑IL‑1αantibodyareinclinicaltrials.MosthumandiseaseisduetochronicinflammationthistherapeutichassincebeenusedtodemonstrateaIL-1receptorantagonist(IL‑1Ra).Anaturallyoccurringresultinginlossoffunctionofajoint,abloodvesse
6、lorroleforIL‑1innumerousdiseases(BOX 1;Supplementaryproteinthatisstructurallyanentireorgan.Insomeorgans,suchastheheartandinformationS1(table)).Anakinracurrentlydominatessimilartointerleukin‑1(IL‑1),brain,acuteinflammationcanbefatal.Interleukin‑1thefieldofIL‑1ther
7、apeuticsowingtoitsexcellentsafetyandinhibitsIL‑1αandIL‑1β(IL‑1)isamastercytokineoflocalandsystemicinflam‑record,shorthalf‑lifeandmultipleroutesofadminis‑activitybyblockingtheIL‑1mation,andtheavailabilityofspecificIL‑1‑targetingtration.NeutralizingIL‑1withantibodi
8、esorsolublereceptor.agentshasrevealedapathologicalroleofIL‑1‑mediatedreceptorshasalsoprovedtobeeffective(TABLE 1),inflammationinagrowinglistofdiseases.andthesolubledecoyreceptorrilonacept(Arcalyst;TherearetworelatedbutdistinctIL‑1genes,IL1ARegeneron)andtheanti‑IL
9、‑1βneutralizingmonoclonalandIL1B,encodingIL‑1αandIL‑1β,respectively.Eachantibodycanakinumab(Ilaris;Novartis)havenowbeenIL‑1bindstothesamecellsurfacereceptor,te
